Introduction
============

The prevalence of antiretroviral drug resistance in drug-naive patients (drug-naive) varies across geographic regions \[[@R1]--[@R7]\]. To monitor transmitted drug resistance (TDR), most studies count the number of surveillance drug resistance mutations (SDRMs) in newly diagnosed \[[@R8]\]. This approach does not analyze transmissibility and transmission source of SDRMs. Different transmissibility of wild-type and SDRM-containing viruses has been reported \[[@R9]--[@R11]\]. These likely result from different reversion dynamics and fitness costs in absence of drugs. First-line treatment guidelines assume that drug-naive patients with TDR, infected directly from patients failing treatment, harbor undetected SDRMs as minority variants and suggest avoiding low genetic barrier regimens, even if DRMs against such regimens are not observed \[[@R12],[@R13]\]. More treatment options could be available if it could be shown that those patients acquired TDR from other drug-naive patients. To investigate TDR, directly from treatment-failing versus onwards between drug-naive patients, most studies investigate transmission chains \[[@R14]--[@R16]\], which are complicated and require dense sampling. We describe an innovative approach to correlate prevalence of SDRMs in drug-naive and treatment-failing patients, providing understanding of transmissibility and reversion dynamics. We use robust linear regression to measure transmissibility and source of SDRMs, which does not require dense sampling.

Methods
=======

The protocol was in accordance with the Declaration of Helsinki and approved by Ethical Committees of Centro Hospitalar de Lisboa Ocidental (108/CES-2014) and KU Leuven, Faculty of Medicine (NH019/2015--06--01). We used a database containing anonymized patients' clinical and HIV-1 sequence data obtained in Portugal between April 2001 and March 2013 for antiretroviral resistance testing. To ensure patients belonged to the same epidemic, analyses were limited to subtype B \[[@R17],[@R18]\]. Of 3606 sequences from 3354 patients, 1685 were from drug-naive and 1921 from treatment-failing patients, using only the first (drug-naive) or last (treatment-failing) sequence per patient. Median age and sex proportion was similar in drug-naive \[43 years, interquartile range (IQR) = 15 years; 75.7% males\] and treatment-failing patients (48 years, IQR = 13 years; 74.1% males). Reproducibility was tested on a previously published German cohort (DE) \[[@R19]\].

TDR mutations were those listed in ref. \[[@R8]\]. Drug-naive patients were patients naive for all drug classes, whereas treatment-failing patients were patients experienced with the drug class of interest. Prevalence in treatment-failing patients is presented per drug class (Fig. [1](#F1){ref-type="fig"}) or, for comparison between drug classes, normalized for the complete treated population (Table [1](#T1){ref-type="table"}, Fig. S1, for Portugal and S2, for DE).

![Robust regression model for the Portuguese cohort, relating prevalence of SDRMs (codon position) in treatment-failing patients per drug class versus prevalence of SDRMs in drug-naive patients.](aids-29-2045-g001){#F1}

For each SDRM, we evaluated two measures of transmissibility: transmission ratio (Table [1](#T1){ref-type="table"}), prevalence in drug-naive patients divided by prevalence in patients failing treatment containing that drug class; regression model for each drug class, correlating SDRMs prevalence in drug-naive and treatment-failing patients, with outlier detection (Fig. [1](#F1){ref-type="fig"} and S1 for Portugal, Fig. S2, for DE).

To evaluate the viral load effect, we correlated viral load of patients with SDRMs and transmission ratio for those SDRMs. Analyses were performed considering viral load of drug-naive, treatment-failing (Fig. S3, ) or drug-naive + treatment-failing patients containing SDRMs.

For statistical analyses, SAS, R and Rpy2 interface for Python were used \[[@R20]--[@R23]\]. Outliers were identified with robust linear regression (ROBUSTREG, SAS) assuming prevalence in treatment-failing patients as fixed and independent.

Results
=======

The prevalence of TDR in Portugal was 10.0% (95% confidence interval (CI): 8.6--11.5\], whereas 67.7% of treatment-failing patients \[65.5--69.8\] carried SDRMs. Most TDR was single \[7.4%, (6.2--8.8%); 5.4% singletons\], followed by double \[2.2% (1.6--3.0%)\] and triple class resistance \[0.4% (0.1--0.8%)\]. In treatment-failing patients, 18.6% (16.9--20.4%) had single class resistance, 1.9% singletons; 38.4% (36.2--40.6%) double and 10.7% (9.3--12.1%) triple class resistance. SDRMs with highest prevalence in drug-naive patients were L90 M (1.4%) for protease inhibitors, T215Y/F + Rev (Rev = C, D, E, I, S, V) (2.6%) for nucleoside reverse transcriptase inhibitors, (NRTIs) and K103N/S (2.3%) for nonnucleoside reverse transcriptase inhibitors, (NNRTIs). In treatment-failing patients, SDRMs with highest prevalence were L90 M (19.7%), M184I/V (44.0%) and K103N/S (32.3%). Highest transmission ratios were observed for N83D (0.165), N88D/S (0.134) and D30N (0.130) for protease inhibitors; T215Rev (0.727) (for T215Y/F was 0.029) and V75A/M/S/T (0.120) for NRTIs; and K101E/P (0.092) and G190A/E/S (0.091) for NNRTIs (Table [1](#T1){ref-type="table"}).

We found a significant linear correlation between prevalence of SDRMs in drug-naive versus treatment-failing patients, indicating that prevalence in drug-naive patients can be predicted from prevalence in treatment-failing patients from the same epidemic. In the Portugal regression model \[Fig. [1](#F1){ref-type="fig"} (drug class specific) and S1 (normalized)\], the *R*^2^ ranged between 0.52 (protease inhibitors) and 0.68 (NNRTIs). After normalizing for treatment, the regression slope was higher for NNRTIs (0.116), followed by NRTIs (0.084) and protease inhibitors (0.073) (Fig. S1, ). In each class-specific analysis, some SDRMs were classified as outliers: for protease inhibitors, D30N, N88D/S, and L90 M were above; for NRTIs, M184I/V was below; and for NNRTIs G190A/E/S was above the regression line (Table S1, ).

In the normalized regression model for DE \[[@R19]\] (Fig. S2, ), the slope was also higher for NNRTIs (0.08) followed by NRTIs (0.07). Outliers and positioning of mutations were consistent with Portugal for NRTIs (Fig. S2B, ) and for NNRTIs (Fig. S2C, ). For NRTIs, K219N and T215rev were consistently above, whereas K70E, M184I/V, L210W and T215Y/F were below the CI (see Fig. [1](#F1){ref-type="fig"}B and S2B, for outlier classification). Mutations M41L (above) and L74I/V (below) were outside the CI for Portugal but not for DE, and T69N (above) and K65R (below) were outside the CI for DE but not for Portugal. For NNRTIs, Y181C/I/V was below the CI and G190A/E/S was above the CI in both cohorts. K101P was above the CI for Portugal and not for DE and V106I below the CI for DE but not Portugal. There were no SDRMs significantly on opposite sides of the regression line when comparing cohorts. For protease inhibitors (Fig. [1](#F1){ref-type="fig"}A and S2A, ), preliminary analysis showed important differences between cohorts that we could not analyze further, as access to DE data was limited (only DRMs with a prevalence \>0.3% were reported in \[[@R19]\]). It has to be noted that in the German cohort, all subtypes were considered together, whereas we only analyzed the subtype B epidemic. Additionally, other SDRMs may have spread in transmission clusters among drug-naive.

We found no significant correlation between the transmission ratio of specific SDRMs and the viral load of individuals carrying such SDRMs in samples taken at most 30 days before or after the resistance test (Figure S3, ). The Wilcoxon rank sum test showed no significant differences between the viral load of treatment-failing patients failing different drug classes.

Discussion
==========

We describe a simple and innovative method that compares the prevalence of SDRMs in drug-naive patients with its prevalence in treatment-failing patients. We tested two approaches: SDRM transmission ratios and robust linear regression comparing prevalence of SDRMs in drug-naive and treatment-failing patients. We analyzed Portuguese subtype B patients; thus, drug-naive and treatment-failing patients belong to the same epidemic \[[@R24]\], and confirmed the approach using a German cohort \[[@R19]\]. Yet, specificity and reproducibility should be tested in more cohorts.

SDRM transmission ratios were high for SDRMs with high transmissibility (e.g. 0.727 for T215Rev, Table [1](#T1){ref-type="table"}); however, precision was low for SDRMs with low prevalence in treatment-failing patients: N83D has a high transmission ratio (0.165) but was only found in one drug-naive and five treatment-failing patients, with large CI. Thus, transmission ratios can only give reliable indications of transmissibility for mutations highly prevalent in treatment-failing patients.

Robust regression indicated the prevalence of SDRMs in drug-naive and treatment-failing patients to be linearly correlated (Fig. [1](#F1){ref-type="fig"}), suggesting that prevalence in treatment-failing patients can be used for surveillance and predicts TDR levels. Our model can be analyzed:

First, comparing regression slopes between drug classes, as an indication of the overall transmissibility of DRMs of one drug class compared with others. Although faster reversion dynamics result in reduced slopes, increased onward transmission among drug-naive patients results in steeper slopes. However, as the slope also varies according to cohort-specific treatment strategies, we built an additional model normalizing prevalence in treatment-failing patients to the total population failing treatment (Fig. S1, ). If SDRMs would not affect fitness in absence of drugs, the normalized slope should be similar between drug classes. Differences can then be explained by different reversion dynamics of SDRMs to different drug classes, impacting rates of onward transmission. In both cohorts, the NNRTI-normalized slope is higher than the NRTI\'s, consistent with higher persistence of NNRTI mutations \[[@R25]\]. We found, however, that the protease inhibitor model may be more cohort-dependent.

Second, outlier detection within drug class: an SDRM found more often in drug-naive patients than expected from prevalence in treatment-failing patients, meaning it is found above the regression line, suggests that its prevalence in drug-naive patients increased by onward transmission among drug-naive patients, indicating higher transmissibility than other DRMs to the same drug class. This mutation has a lower reversion rate after transmission because of lower fitness cost. If the SDRM is found below the regression line, meaning it is occurs less frequently in drug-naive patients than expected from its prevalence in treatment-failing patients, it is transmitted less often and/or reverses faster because of higher fitness cost in absence of the drug.

Our results are consistent with other studies: M184I/V has been shown to have low persistence after transmission to drug-naive patients; G190A has been shown to have high persistence \[[@R26]--[@R29]\]. We show here that D30N, N88D/S and L90 M also have high transmissibility and that other SDRMs have higher (M41L, T215Rev and K219E/N/Q/R for NRTIs and K101E/P for the NNRTIs) or lower transmissibility (K70E/R, L74I/V, and T215Y/F for NRTIs; Y181C/I/V for NNRTIs and I84 V and I54A/L/M/S/T/V for protease inhibitors) compared with other mutations of the same drug class. T215Rev and T215Y/F are above and below the regression line respectively, supporting our model, as T215Y/F has a fitness cost in absence of drug and reverts after transmission into one of the T215Rev mutants with less onward transmission of T215Y/F between drug-naive patients \[[@R30]\]. Our findings are confirmed with the German cohort, wherein mostly the same mutations fall above or below the regression line.

This is the first time the correlation of SDRM prevalence in treatment-failing and drug-naive patients is used to make claims on transmissibility and source of acquisition of TDR. Other studies investigating transmission ratios only considered treatment-failing patients as source of SDRMs \[[@R9],[@R11]\]. Our approach enables identification of SDRMs for which drug-naive patients are a likely additional source.

Our results support that for first-line treatment strategies, prevalence of SDRMs in local treatment-failing patients should be considered given the linear correlation with prevalence in drug-naive patients. This is more practical than only counting SDRMs in drug-naive patients because: the prevalence of SDRMs in treatment-failing patients is higher than in drug-naive patients and therefore the CI is smaller; many drug-naive patients have not been diagnosed and therefore sampled; although most treatment-failing patients are tested for drug resistance immediately at treatment failure, in many countries, most drug-naive patients are either not tested or tested only just before starting treatment when eventual reversion already took place. Our approach is therefore especially useful for resource-limited settings.

In conclusion, correlating the prevalence of SDRMs in drug-naive and treatment-failing patients gives a refined view of the transmission dynamics, persistence, viral fitness and source of TDR, which could help public health and strategic measures to avoid increasing TDR. Future efforts should include the development of more sophisticated statistical models to address the uncertainty associated with less frequent SDRMs.
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###### Supplemental Digital Content

###### 

Overview of the SDRMs identified in the Portuguese cohort, at each position for each drug class with prevalence and transmission ratios.

  **Protease inhibitor**                                                                                                                                                          
  ----------------------------- --------------------------------------------- ------------------------------------------------- ------------------------------------------------- ---------
  83D                           0.1 (0.0--0.3) (N = l)                        0.4 (0.1--0.9) (N = 5)                            0.3 (0.1--0.6) (N = 5)                            0.2
  **88D/S**                     **0.7** (**0.4--1.2**) **(N** **=** **12)**   **5.3** (**4.2-S.7**) **(N** **=** **72)**        **3.7** (**2.9--4.7**) **(N** **=** **72)**       **0.1**
  30N                           **0.7** (**0.4--1.2**) **(N** **=** **12)**   **5.5** (**4.3-S.8**) **(N** **=** **74)**        **3.9** (**3.0--4.8**) **(N** **=** **74)**       **0.1**
  **32I**                       **0.3** (**0.1--0.7**) **(N** **=** **5)**    **3.0** (**2.2--4.1**) **(N** **=** **41)**       **2.1** (**1.5--2.9**) **(N** **=** **41)**       **0.1**
  24I                           0.2 (0.1--0.6) (N = 4)                        2.7 (1.9--3.8) (N = 37)                           1.9 (1.4--2.6) (N = 37)                           0.1
  85V                           0.2 (0.0--0.5) (N = 3)                        2.5 (1.7--3.5) (N = 34)                           1.7 (1.2--2.5) (N = 34)                           0.1
  **90M**                       **1.4** (**0.9--2.0**) **(N** **=** **23)**   **19.7** (**17.6--21.9**) **(N** **=** **266)**   **13.8** (**12.3--15.5**) **(N** **=** **266)**   **0.1**
  46I/L                         0.9 (0.5--1.5) (N = 16)                       17.5 (15.5--19.7) (N = 237)                       12.3 (10.9--13.9) (N = 237)                       0.1
  53L/Y                         0.1 (0.0--0.4\] (N = 2)                       2.4 (1.6--3.3) (N = 32)                           1.7 (1.1--2.3) (N = 32)                           0.1
  82A/C/F/L/M/S/T               0.8 (0.4--1.3) (N = 13)                       15.5 (13.5--17.5) (N = 209)                       10.8 (9.5--12.4) (N = 209)                        0.1
  **54A/L/M/S/T/V**             **0.5** (**0.2--1.0**) **(N** **=** **9)**    **16.0** (**14.1--18.0**) **(N** **=** **216)**   **11.2** (**9.9--12.7**) **(N** **=** **216)**    **0.0**
  48M/V                         0.1 (0.0--0.3) (N = l)                        2.0 (1.3--2.9) (N = 27)                           1.4 (0.9--2.0) (N = 27)                           0.0
  **84V**                       **0.1** (**0.0--0.4**) **(N** **=** **2)**    **6.2** (**5.0--7.6**) **(N** **=** **84)**       **4.4** (**3.5--5.4J (N** **=** **84)**           **0.0**
  **73A/C/S/T**                 **0.1** (**0.0--0.3**) **(N** **=** **1)**    **7.0** (**5.7--8.5**) **(N** **=** **95)**       **4.9** (**4.0--6.0**) **(N** **=** **95)**       **0.0**
  23I                           0.0 (0.0--0.2) (N = 0)                        0.7 (0.3--1.3) (N = 9)                            0.5 (0.2--0.9) (N = 9)                            0.0
  47A/V                         0.0 (0.0--0.2) (N = 0)                        2.2 (1.5--3.2) (N = 30)                           1.6 (1.1--2.2) (N = 30)                           0.0
  50L/V                         0.0 (0.0--0.2) (N = 0)                        1.2 (0.7--1.9) (N = 16)                           0.8 (0.5--1.3) (N = 16)                           0.0
  76V                           0.0 (0.0--0.2) (N = 0)                        1.5 (0.9--2.3) (N = 20)                           1.0 (0.6--1.6) (N = 20)                           0.0
  Any protease inhibitor-SDRM   3.5 (2.7--4.5) (N = 59)                       38.3 (35.7--41.0) (N = 518)                       27.0 (25.0--29.0) (N = 518)                       

  **NRTI**                                                                                                                                                                  
  ---------------------- --------------------------------------------- -------------------------------------------------- ------------------------------------------------- ---------
  **215rev**             **1.8** (**1.2--2.5**) **(N** **=** **30)**   **2.4** (**1.8--3.2**) **(N** **=** **47)**        **2.4** (**1.8--3.2**) **(N** **=** **47)**       **0.7**
  75A/M/S/T              0.2 (0.1--0.6) (N = 4)                        2.0 (1.4--2.7) (N = 38)                            2.0 \[1.4--2.7) (N = 38)                          0.1
  **219E/N/Q/R**         **1.2** (**0.8--1.9**) **(N** **=** **21)**   **13.8** (**12.2--15.4**) **(N** **=** **264)**    **13.7** (**12.2--15.4**) **(N** **=** **264)**   **0.1**
  **41L**                **2.1** (**1.5--2.9**) **(N** **=** **35)**   **23.3** (**21.4--25.2**) **(N** **=** **447)**    **23.3** (**21.4--25.2**) **(N** **=** **447)**   **0.1**
  69D                    0.2 (0.1--0.6) (N = 4)                        2.7 (2.0--3.5) (N = 52)                            2.7 (2.0--3.5) (N = 52)                           0.1
  215Y/F** **+** **rev   2.6 (1.9--3.5) (N = 44)                       31.3 (29.2--33.4) (N = 600)                        31.2 (29.2--33.4) (N = 600)                       0.1
  67E/G/N                1.4 (0.9--2.1) (N = 24)                       20.7 (18.9--22.6) (N = 398)                        20.7 (18.9--22.6) (N = 398)                       0.1
  **210W**               **0.8** (**0.4--1.3**) **(N** **=** **13)**   **15.6** (**14.0--17.3**) **(N** **=** **300)**    **15.6** (**14.0--17.3**) **(N** **=** **300)**   **0.0**
  151M                   0.1 (0.0--0.3) (N = 1)                        1.7 (1.1--2.3) (N = 32)                            1.7 (1.1--2.3) (N = 32)                           0.0
  **215Y/F**             **0.8** (**0.5--1.4**) **(N** **=** **14)**   **28.8** (**26.8--30.9**) **(N** **=** **553)**    **28.8** (**26.8--30.9**) **(N** **=** **553)**   **0.0**
  **184I/V**             **1.2** (**0.8--1.9**) **(N** **=** **21)**   **44.0** ((**41.7--46.2**) **(N** **=** **844)**   **43.9** (**41.7--46.2**) **(N** **=** **844)**   **0.0**
  **70E/R**              **0.2** (**0.1--0.6**) **(N** **=** **4)**    **12.4** (**11.0--14.0**) **(N** **=** **238)**    **12.4** (**10.9--13.9**) **(N** **=** **238)**   **0.0**
  **74I/V**              **0.1** (**0.0--0.3**) **(N** **=** **l)**    **7.4** (**6.3--8.7**) **(N** **=** **142)**       **7.4** (**6.3--8.7**) **(N** **=** **142)**      **0.0**
  65R                    0.0 (0.0--0.2) (N = 0)                        2.7 (2.0--3.5) (N = 52)                            2.7 (2.0--3.5) (N = 52)                           0.0
  77L                    0.0 (0.0--0.2) (N = 0)                        0.9 (0.5--1.4) (N = 17)                            0.9 (0.5--1.4) (N = 17)                           0.0
  115F                   0.0 (0.0--0.2) (N = 0)                        1.6 (1.1--2.3) (N = 31)                            1.6 (1.1--2.3) (N = 31)                           0.0
  116Y                   0.0 (0.0--0.2) (N = 0)                        1.4 (0.9--2.0) (N = 26)                            1.4 (0.9--2.0) (N = 26)                           0.0
  Any NRTI-SDRM          5.0 (4.0--6.2) (N = 85)                       61.1 (58.9--63.3) (N = 1174)                       61.1 (58.9--63.3) (N = 1174)                      

  **NNRTI**                                                                                                                                                         
  ---------------- --------------------------------------------- ------------------------------------------------- ------------------------------------------------ ---------
  **101E/P**       **0.6** (**0.3--1.1**) **(N** **=** **10)**   **6.5** (**5.2--8.0**) **(N** **=** **80)**       **4.2** (**3.3--5.2**) **(N** **=** **80)**      **0.1**
  **190A/E/S**     **1.4** (**0.9--2.1**) **(N** **=** **24)**   **15.6** (**13.6--17.7**) **(N** **=** **193)**   **10.0** (**8.7--11.5**) **(N** **=** **193)**   **0.1**
  103N/S           2.3 (1.6--3.1) (N = 38)                       32.3 (29.7--34.9) (N = 399)                       20.8 (19.0--22.7) (N = 399)                      0.1
  225H             0.2 \[0.0--0.5) (N = 3)                       3.2 (2.3--4.3) (N = 39)                           2.0 (1.4--2.8) (N = 39)                          0.1
  **181C/I/V**     **0.6** (**0.3--1.1**) **(N** **=** **10)**   **12.4** (**10.7--14.4**) **(N** **=** **154)**   **8.0** (**6.8--9.3**) **(N** **=** **154)**     **0.0**
  188C/H/L         0.2 (0.0--0.5) (N = 3)                        5.2 (4.0--6.6) (N = 64)                           3.3 (2.6--4.2) (N = 64)                          0.0
  100I             0.0 (0.0--0.2) (N = 0)                        4.1 (3.1--5.4) (N = 51)                           2.7 (1.9--3.5) (N = 51)                          0.0
  106A/M           0.0 (0.0--0.2) (N = 0)                        2.7 (1.8--3.7) (N = 33)                           1.7 (1.2--2.4) (N = 33)                          0.0
  230L             0.0 (0.0--0.2) (N = 0)                        1.1 (0.6--1.8) (N = 13)                           0.7 (0.4--1.2) (N = 13)                          0.0
  Any NNRTI-SDRM   4.3 (3.4--5.4) (N = 73)                       57.8 (55.0--60.6) (N = 715)                       37.2 (35.1--39.4) (N = 715)                      

Bold entries indicate an SDRM located above or below the 95% CI in the robust linear regression (Fig. [1](#F1){ref-type="fig"}). Variants at a single position are pooled (e.g. 46I/L). CI, confidence interval; NNRTI, nonnucleoside reverse transcriptase inhibitors; NRTI, nucleoside reverse transcriptase inhibitors; SDRM, surveillance drug resistance mutations.
